Other important issues are to define the clinical correlates of liver cancers that show deficient Mst1/2-Yap regulation (Xu et al, 2009), and to determine whether there are druggable targets in this pathway, for example, upstream of Mst1/2 or downstream of Yap1. The gene discussed is YAP1; the disease is liver cancer.